Drugs / BMS-986156
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04021043 | Aug 2019 → Apr 2025 | carcinoma of liver and intrahepatic biliary tract, lung carcinoma, metastatic malignant neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02598960 | Oct 2015 → Dec 2019 | cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986156 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04021043 ↗ |
| Action | Activate | “BMS-986156 is a fully agonistic human immunoglobulin G subclass 1 monoclonal antibody targeting GITR.” PMID 36863094 ↗ Feb 2023 |
| Modality | Monoclonal antibody | “BMS-986156 is a fully agonistic human immunoglobulin G subclass 1 monoclonal antibody targeting GITR.” PMID 36863094 ↗ Feb 2023 |
| Route | Intravenous | “The protein agonist BMS-986156 was administered intravenously at a dose of 10, 30, 100, 240, or 800 mg every 2 weeks as monotherapy” PMID 31697308 ↗ Jan 2020 |
| Target | TNFRSF18 | “TNFRSF18 Agonist BMS-986156” NCT04021043 ↗ |